Information Provided By:
Fly News Breaks for June 12, 2015
QDEL
Jun 12, 2015 | 07:38 EDT
Canaccord believes the long-term risk/reward for Quidel remains positive. The firm cites a positive update about Sofia placements into a number of retail clinics, M&A potential and expectations for the summer launch of its Solana molecular instrument. Canaccord reiterated its Buy rating and $27 price target on Quidel shares.
News For QDEL From the Last 2 Days
There are no results for your query QDEL